Post by
C10H12N2 on Dec 29, 2022 1:17pm
Has shareholders dodge an ever deeper lodged bullet?
It wouldn't surprise me if Algernon Pharmaceuticals has or will consider Christopher Temple (neo-Nazi) as yet another "Business Advisor" and/or some other contractual arrangement to wheel him in as an in-house investment mouthpiece. Algernon's current "Business Advisor" is the recently re-signed CEO of Xortx Therapeutics. Since their successful uplist to NASDAQ (yeah it can be done) see where they're trading now. Hint, they're barreling fast towards a Delisting. Xortx is at the Phase 3 clinical trial stage with a 12M USD market cap last I checked. Surely, CEO's everywhere are clamoring for some of that paid advice.